ReviewJournal of nanobiotechnology2026
Advanced strategies for the diagnosis, treatment, and vaccination of monkeypox.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rpf-Toxo: A Preliminary Computationally Designed Dense Granule Antigen-Based Multi-Epitope Vaccine Against Toxoplasma gondii.Veterinary medicine and science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Monkeypox (Mpox), a zoonotic disease caused by the mpox virus, has been endemic mainly in West and Central Africa for a long time, with only a few cases in other parts of the world. However, recent multi-country outbreaks in non-endemic areas have escalated Mpox into a significant global public health concern. The rapid transmission highlights the urgent need for robust strategies governing diagnosis, treatment, and prevention. In this review, we synthesized advanced approaches addressing the Mpox challenge, focusing on the application of emerging technologies. We examined the integration of nanotechnology, nucleic acid amplification techniques (NAATs), gene editing technology and sequencing technology in Mpox prevention and control. These platforms offered promising solutions to critical limitations in current Mpox control, including high detection costs, poor drug specificity, and suboptimal vaccine efficacy. Finally, we outlined the outlook and potential development trajectories for sustained Mpox prevention and control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.